Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Narcolepsy With Cataplexy
Interventions
Xyrem
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
7 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
17
States / cities
Long Beach, California • Orange, California • Redwood City, California + 14 more
Conditions
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions
ORX750, Placebo
Drug
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Auburn, Alabama • Chandler, Arizona • Scottsdale, Arizona + 24 more
Conditions
Narcolepsy
Interventions
Armodafinil
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 18 more
Conditions
Healthy, Narcolepsy
Interventions
MK-6552, MK-6552 placebo, Modafinil, Modafinil placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Atlanta, Georgia • Eatontown, New Jersey
Conditions
Narcolepsy, Sleep Apnea, Obstructive
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 16 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Conditions
Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke, Ischemic Attack, Transient
Interventions
NXY-059
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 95 more
Conditions
Narcolepsy Type 2
Interventions
Placebo, TAK-861 2 mg, TAK-861 2 mg and 5 mg
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 18 more
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiologic Correlates of Hypersomnia

NCT01719315
Conditions
Major Depressive Disorder, Primary Hypersomnia, Bipolar Disorder, Narcolepsy, Primary Insomnia
Interventions
Acoustical slow wave induction
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Narcolepsy Type 1
Interventions
TAK-861, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 70 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • Redwood City, California • Santa Ana, California + 12 more
Conditions
Excessive Daytime Sleepiness, Cataplexy, Narcolepsy
Interventions
FT218, Placebo
Drug
Lead sponsor
Avadel
Industry
Eligibility
16 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
38
States / cities
Anniston, Alabama • Auburn, Alabama • Birmingham, Alabama + 32 more
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human Study of VX-433

NCT07584434
Conditions
Narcolepsy Type 1 (NT1)
Interventions
VX-433, Placebo, Midazolam, Bupropion
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
Interventions
TAK-861, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
11
States / cities
Redwood City, California • Brandon, Florida • Miami, Florida + 8 more
Conditions
Narcolepsy Type 2
Interventions
TAK-360, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
31
States / cities
Auburn, Alabama • Chandler, Arizona • Chula Vista, California + 26 more
Conditions
Healthy, Narcolepsy
Interventions
MK-6552, Modafinil
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Recruiting No phase listed Observational

WAKIX® (Pitolisant) Pregnancy Registry

NCT05536011
Conditions
Pregnancy Related, Narcolepsy
Interventions
Pitolisant, Comparator Products
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
Female only
Enrollment
1,329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Morrisville, North Carolina
Conditions
Narcolepsy, Excessive Daytime Sleepiness, Cataplexy Narcolepsy
Interventions
mazindol extended release, Placebo
Drug
Lead sponsor
NLS Pharmaceutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more
Conditions
Narcolepsy
Interventions
ADX-N05, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 23 more
Conditions
Narcolepsy Type 1
Interventions
TAK-861, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
21
States / cities
Birmingham, Alabama • Redwood City, California • Santa Ana, California + 18 more
Conditions
Healthy Volunteers, Narcolepsy Type 1
Interventions
Portable EEG Device, Portable ECG Device, Accelerometry
Device
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
13
States / cities
Redwood City, California • Colorado Springs, Colorado • Clearwater, Florida + 9 more
Conditions
Narcolepsy
Interventions
SEP363856, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Orange, California • St. Petersburg, Florida • Atlanta, Georgia + 3 more
Terminated Phase 2 Interventional Results available

A Study of TAK-994 in Adults With Narcolepsy

NCT04820842
Conditions
Narcolepsy Type 1 (NT 1)
Interventions
TAK-994, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
35
States / cities
Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 29 more
Conditions
Narcolepsy
Interventions
JZP258
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Culver City, California • Encino, California • Huntington Beach, California + 27 more
Conditions
Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
Interventions
AXS-12 (reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
15 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
47
States / cities
Alabaster, Alabama • Peoria, Arizona • Phoenix, Arizona + 43 more
Conditions
Narcolepsy
Interventions
Not listed
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Palo Alto, California